Mode
Text Size
Log in / Sign up
N/A Completed N=101 Diagnostic

Dexcom G6 Observational Study

Source: ClinicalTrials.gov NCT03832907 ↗
Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcomePrimary: Mean Daily Blood Glucose by POC Reading сompared to CGM Reading — 175.55; 175.84 mg/dL

Summary

This is an exploratory prospective study primary aiming to evaluate differences between Point-of-care (POC) testing (standard of care) and Dexcom G6 CGM (Continues Glucose Monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperglycemic events - in patients with type 1 and type 2 diabetes treated with basal bolus insulin regimen.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Daily Blood Glucose by POC Reading сompared to CGM Reading
175.55; 175.84
PRIMARY
Number of Clinical Significant Hypoglycemia (<54 mg/dl) Events by POC Reading Compared to CGM Reading
9; 29
PRIMARY
Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading
305; 518
SECONDARY
Mean Daily Blood Glucose by POC Reading Compared to CGM Reading
175.55; 173.13
SECONDARY
Number of Clinical Significant Hypoglycemia (<54 mg/dl) Events by POC Reading Compared to CGM Reading
9; 29
SECONDARY
Number of Clinical Significant Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading
305; 399
SECONDARY
Number of Nocturnal Hypoglycemic Events < 70 mg/dl (Between 22:00 and 06:00) by POC Reading Compared to CGM Reading
1; 22; 9
SECONDARY
Number of of Hypoglycemic Events < 70mg/dl in POC Group by POC Reading Compared to CGM Reading
36; 144; 115
SECONDARY
Number of Hypoglycemic Events < 70mg/dl by POC Reading Compared to CGM Reading
10; 100; 48
SECONDARY
Time in Hypoglycemia (Minutes) During the Day and Night by CGM Reading
118.70; 89.14
SECONDARY
Time in Hyperglycemia (Minutes) During the Day and Night> 240 mg/dl by CGM Reading
4624.3; 1706.1
SECONDARY
Number of Hyperglycemic Events > 240 mg/dl by POC Reading Compared to CGM Reading
153; 554; 316
SECONDARY
Percentage of BG Readings Within Target BG of 70 and 180 mg/dl by POC Reading Compared to CGM Reading
59.56; 52.62; 51.60
SECONDARY
Percentage of Patients With Greater Than 5%-Time Below Glucose Target <70mg/dl by CGM Reading
10; 4.6
SECONDARY
Percentage of Patients With Greater Than 5%-Time Below Glucose Target <70 mg/dl by CGM Reading
5.3; 2.9
SECONDARY
Percentage of Patients With Greater Than 5%-Time Above Glucose Target >180mg/dl by CGM Reading
91; 89
SECONDARY
Percentage of Patients With Greater Than 5%-Time Above Glucose Target >180 mg/dl by CGM Reading
89; 94
SECONDARY
Glycemic Variability Calculated by Standard Deviation by CGM Reading
46.37; 43.87
SECONDARY
Glycemic Variability Calculated by MAGE by CGM Reading
58.73; 56.68
SECONDARY
Number of Sensor Removal/Failures/Dislodgments
31
SECONDARY
Mean Absolute Relative Difference (MARD) of CGM Compared to POC
12.54; 12.22
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 30/30% for Values < 70 mg/d Compared to the Standard-of-care POC BG
89.3; 85.2
SECONDARY
Percentage of Values Within Zone A, B, C, D of the Clarke Error Grid Measured in Abdomen
82.4; 16.5; 0.1; 1
SECONDARY
Percentage of Values Within Zone A, B, C of the Clarke Error Grid Measured in Arm
81.4; 17.6; 0.1; 0.9
SECONDARY
Number of Nocturnal Hypoglycemic Events < 54 mg/dl (Between 22:00 and 06:00) by POC Reading Compared to CGM Reading
0; 8; 3
SECONDARY
Number of of Hypoglycemic Events < 54 in POC Group by POC Reading Compared to CGM Reading
9; 60; 29
SECONDARY
Number of Hypoglycemic Events < 54mg/dl by POC Reading Compared to CGM Reading
3; 48; 16
SECONDARY
Percentage of Patients With Greater Than 5%-Time Below Glucose Target <54mg/dl by CGM Reading
3.4; 0
SECONDARY
Percentage of Patients With Greater Than 5%-Time Above Glucose Target >240 mg/dl by CGM Reading
53; 43
SECONDARY
Percentage of Patients With Greater Than 5%-Time Below Glucose Target <54 mg/dl by CGM Reading
1.8; 2.9
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 30/30% for Values 70-140 mg/dl Compared to the Standard-of-care POC BG
93.1; 92.9
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 30/30% for Values 140-180 mg/dl , Compared to the Standard-of-care POC BG
93.3; 94.9
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 30/30%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG
95.5; 94
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 20/20% for Values < 70 mg/dl Compared to the Standard-of-care POC BG
78.6; 74.1
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 20/20% for Values 70-140 mg/dl Compared to the Standard-of-care POC BG
82.0; 82.0
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 20/20%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG
84.7; 81.1
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 20/20% for Values 140-180 mg/dl , Compared to the Standard-of-care POC BG
83.2; 83.6
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 15/15% for Values < 70 mg/dl Compared to the Standard-of-care POC BG
75.0; 66.7
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 15/15% for Values 70-140 mg/dl Compared to the Standard-of-care POC BG
69.4; 70.5
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 15/15% for Values 140-180 mg/dl , Compared to the Standard-of-care POC BG
69.6; 73.8
SECONDARY
Percentage of Dexcom G6 CGM Sensor Values Within 15/15%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG
71.0; 71.5

Eligibility Criteria

Inclusion Criteria

  • > 18 years admitted to a general medicine or surgical service.
  • Known history of T1D or T2D receiving insulin therapy
  • Subjects must have a randomization BG between 140 mg and 400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate < 18 mEq/L, pH < 7.30, or positive serum or urinary ketones).
  • Patients with expected hospital length-of-stay of 3 or more days

Exclusion Criteria

  • Patients with acute illness admitted to the ICU or expected to require admission to the ICU.
  • Patients expected to require MRI procedures during hospitalization.
  • Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  • Female subjects who are pregnant or breast-feeding at time of enrollment into the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03832907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search